Skip to main content
. 2023 Aug 17;2023:9219067. doi: 10.1155/2023/9219067

Table 1.

Demographic and clinical characteristics of EOC patients included in this study.

Overall (N = 454) Training group (N = 317) Validation group (N = 137) P value
Age (years)
 ≤70 378 (83.3%) 268 (84.5%) 110 (80.3%) 0.329
 ≥71 76 (16.7%) 49 (15.5%) 27 (19.7%)
Race
 White 393 (86.6%) 276 (87.1%) 117 (85.4%) 0.86
 Black 14 (3.1%) 9 (2.8%) 5 (3.6%)
 Others 47 (10.4%) 32 (10.1%) 15 (10.9%)
Marital status
 Married 272 (59.9%) 186 (58.7%) 86 (62.8%) 0.162
 Single 81 (17.8%) 53 (16.7%) 28 (20.4%)
 Others 101 (22.2%) 78 (24.6%) 23 (16.8%)
Histologic type
 Clear cell 20 (4.4%) 13 (4.1%) 7 (5.1%) 0.819
 Endometrioid 21 (4.6%) 14 (4.4%) 7 (5.1%)
 Mucinous 7 (1.5%) 4 (1.3%) 3 (2.2%)
 Serous 406 (89.4%) 286 (90.2%) 120 (87.6%)
Grade
 I 10 (2.2%) 9 (2.8%) 1 (0.7%) 0.658
 II 71 (15.6%) 51 (16.1%) 20 (14.6%)
 III 335(73.8%) 232 (73.2%) 103 (75.2%)
 Unknown 38 (8.4%) 25 (7.9%) 13 (9.5%)
Laterality
 Bilateral 275 (60.6%) 191 (60.3%) 84 (61.3%) 0.554
 Unilateral 156 (34.4%) 112 (35.3%) 44 (32.1%)
 Unknown 23 (5.1%) 14 (4.4%) 9 (6.6%)
FIGO stage
 I/II 28 (6.2%) 20 (6.3%) 8 (5.8%) 1
 III/IV 426 (93.8%) 297 (93.7%) 129 (94.2%)
T stage
 T1 12 (2.6%) 10 (3.2%) 2 (1.5%) 0.785
 T2 26 (5.7%) 18 (5.7%) 8 (5.8%)
 T3 118 (26.0%) 82 (25.9%) 36 (26.3%)
 T4 298 (65.6%) 207 (65.3%) 91 (66.4%)
N stage
 N0 137 (30.2%) 98 (30.9%) 39 (28.5%) 0.682
 N1 317 (69.8%) 219 (69.1%) 98 (71.5%)
M stage
 M0 272 (59.9%) 194 (61.2%) 78 (56.9%) 0.455
 M1 182 (40.1%) 123 (38.8%) 59 (43.1%)
Surgical approach
 PE 40 (8.8%) 34 (10.7%) 6 (4.4%) 0.188
 APE 13 (2.9%) 7 (2.2%) 6 (4.4%)
 PPE 357 (78.6%) 246 (77.6%) 111 (81.0%)
 TPE 38 (8.4%) 26 (8.2%) 12 (8.8%)
 EPE 6 (1.3%) 4 (1.3%) 2 (1.5%)
Radiotherapy
 No/unknown 449 (98.9%) 314 (99.1%) 135 (98.5%) 1
 Yes 5 (1.1%) 3 (0.9%) 2 (1.5%)
Chemotherapy
 No/unknown 80 (17.6%) 58 (18.3%) 22 (16.1%) 0.66
 Yes 374 (82.4%) 259 (81.7%) 115 (83.9%)
CA125
 Positive 370 (81.5%) 260 (82.0%) 110 (80.3%) 0.484
 Negative 16 (3.5%) 9 (2.8%) 7 (5.1%)
 Unknown 68 (15.0%) 48 (15.1%) 20 (14.6%)
Lymph nodes examined
 1∼12 154 (33.9%) 108 (34.1%) 46 (33.6%) 0.953
 13∼25 139 (30.6%) 98 (30.9%) 41 (29.9%)
 ≥26 161 (35.5%) 111 (35.0%) 50 (36.5%)
Lymph nodes positive
 0∼8 356 (78.4%) 254 (80.1%) 102 (74.5%) 0.221
 ≥9 98 (21.6%) 63 (19.9%) 35 (25.5%)
LNR
 (0, ≤0.03) 150 (33.0%) 109 (34.4%) 41 (29.9%) 0.651
 (>0.03, ≤0.32) 146 (32.2%) 100 (31.5%) 46 (33.6%)
 (>0.32, 1.00) 158 (34.8%) 108 (34.1%) 50 (36.5%)
LODDS
 (−2.25, ≤−1.18) 124 (27.3%) 91 (28.7%) 33 (24.1%) 0.551
 (>−1.18, ≤−0.25) 183 (40.3%) 127 (40.1%) 56 (40.9%)
 (>−0.25, 2.26) 147 (32.4%) 99 (31.2%) 48 (35.0%)
Tumor size (mm)
 <38 62 (13.7%) 46 (14.5%) 16 (11.7%) 0.245
 ≥38 288 (63.4%) 205 (64.7%) 83 (60.6%)
 Unknown 104 (22.9%) 66 (20.8%) 38 (27.7%)